NASDAQ:XBIO Xenetic Biosciences Q3 2026 Earnings Results & Report $1.67 +0.01 (+0.84%) Closing price 11/13/2026 03:59 PM EasternExtended Trading$1.72 +0.05 (+3.05%) As of 11/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Xenetic Biosciences reported Q3 2026 earnings on November 12, 2026. The company reported EPS of -$0.72, while revenue was $725.26 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 12, 2026TimeAfter Market ClosesConference Call7:00 AM ET Xenetic Biosciences EPS ResultsActual EPS-$0.72Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersXenetic Biosciences Revenue ResultsActual Revenue$725.26 thousandExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Xenetic Biosciences Q3 2026 Earnings FAQ Did Xenetic Biosciences beat earnings estimates for Q3 2026? Xenetic Biosciences (NASDAQ:XBIO) reported earnings of -$0.72 per share for Q3 2026. The report was announced on Thursday, November 12, 2026. What was Xenetic Biosciences' revenue for Q3 2026? Xenetic Biosciences reported revenue of $725.26 thousand for Q3 2026. Xenetic Biosciences Earnings HeadlinesXenetic Biosciences Announces Oral Presentation at 68th ASH Annual Meeting Highlighting DNase I as a Potential Strategy to Overcome CAR T-Cell ResistanceNovember 4, 2026 | finance.yahoo.comXenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in ...October 15, 2026 | finance.yahoo.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.November 15 at 1:00 AM | Porter & Company (Ad)Xenetic To Acquire Santersus In All-Stock Deal To Advance NET-Focused PipelineSeptember 17, 2026 | rttnews.comXenetic Biosciences y Santersus AG acuerdan crear un líder global en terapias contra las NETSeptember 16, 2026 | es.finance.yahoo.comXenetic Biosciences announces all-stock merger with Santersus, leaving existing shareholders with 15% stakeSeptember 16, 2026 | msn.comSee More Xenetic Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Xenetic Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xenetic Biosciences and other key companies, straight to your email. Email Address About Xenetic BiosciencesXenetic Biosciences (NASDAQ:XBIO) is a clinical-stage biopharmaceutical company focused on developing treatments for oncology indications. The company’s primary focus is its XCART platform, an autologous cell-therapy technology designed to modify a patient’s own T cells to recognize and attack cancer cells. Xenetic has applied the XCART platform to potential treatments for B-cell malignancies, including programs intended to target specific antigens found on cancerous B cells. The company’s research and development activities have centered on advancing personalized immunotherapies through preclinical and clinical development. Historically, Xenetic has also developed drug-delivery technologies, including its PolyXen platform, which was designed to extend the circulation time of therapeutic proteins and potentially improve dosing convenience and treatment performance. The company is based in the United States and has focused primarily on biotechnology research, development and strategic collaborations rather than commercializing a broad portfolio of marketed medicines.View Xenetic Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?YETI Beat on Earnings, But Its Sales Tell a Different StoryCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
